Metabolomic Profiling for Colorectal Cancer Diagnosis

Metabolomic profiling offers a powerful lens for detecting biochemical perturbations associated with colorectal cancer (CRC) and for identifying novel diagnostic biomarkers. By measuring small-molecule metabolites in clinical specimens such as blood, urine or tissue, this approach captures the end products of genomic, transcriptomic and proteomic alterations. Advances in mass spectrometry and nuclear magnetic resonance (NMR) have enabled both non-targeted surveys of the global metabolome and targeted quantification of predefined metabolite panels. In CRC, characteristic changes include alterations in amino acid turnover, lipid species, tricarboxylic acid cycle intermediates and redox metabolites. These shifts often precede macroscopic tumour development, supporting the utility of metabolite signatures for early detection, risk stratification and treatment monitoring. Integrating metabolomic data with conventional markers enhances sensitivity and specificity, while mechanistic studies of dysregulated pathways can reveal new therapeutic targets. The global significance of this work lies in its potential to deliver minimally invasive, cost-effective screening tools and to personalise patient management across diverse healthcare settings.

Research from Nature Portfolio

Urine-based NMR metabolomics has demonstrated excellent performance in distinguishing pre-invasive colorectal neoplasia and advanced disease from healthy controls. Using orthogonal projections to latent structures discriminant analysis, a class-prediction model achieved over 95% sensitivity and specificity for advanced adenoma and early-stage CRC. Key discriminant metabolites included taurine, alanine and 3-aminoisobutyrate, each showing substantial areas under the receiver operating characteristic curve. These findings underscore the promise of non-invasive urinary metabolite panels as screening assays capable of detecting neoplastic changes before clinical symptoms arise.

Metabolomic Profiling for Colorectal Cancer Diagnosis publication trend

The graph below shows the total number of articles in metabolomic profiling for colorectal cancer diagnosis across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomic profiling: Comprehensive analysis of small-molecule metabolites in biological samples to reflect physiological or pathological states.

Targeted metabolomics: Quantitative measurement of a predefined set of metabolites using specific analytical methods.

Non-targeted metabolomics: Global survey of metabolites without prior selection, often for hypothesis generation.

Biomarker: A measurable molecule indicating a biological or pathological process, used for diagnosis or prognosis.

Area under the curve (AUC): A metric from receiver operating characteristic analysis representing diagnostic test accuracy, with 1.0 indicating perfect discrimination.

References

1. Hypoxia-induced cysteine metabolism reprogramming is crucial for the tumorigenesis of colorectal cancer. Redox Biology (2024).
2. Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection. npj Precision Oncology (2024).
3. Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics. Journal of Translational Medicine (2023).
4. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer. Scientific Reports (2019).